Zevalin: the first radioimmunotherapy approved for the treatment of lymphoma.
Zevalin: the first radioimmunotherapy approved for the treatment of lymphoma.
复制标题
DOI：
10.1586/14737140.2.5.485
复制
发表时间：
2002-10-01
影响因子：
3.3
通讯作者：
Grillo-Lopez, Antonio J
中科院分区：
文献类型：
--
作者：
Grillo-Lopez, Antonio J
结合抗体已经在临床试验中超过30年。免疫毒素、化疗偶联物和放射免疫疗法已被评估。Zevalin是第一种用于治疗非霍奇金淋巴瘤（NHL）的结合抗体（也是第一种用于癌症的放射免疫疗法），于2002年2月19日获得美国FDA批准（正在等待EEC的批准）。Zevalin（90 Yttrium ibritumomab tiuxetan）自1992年以来一直在进行临床试验。已经进行了几项研究，包括一项随机III期试验，其中显示其在总体缓解率和完全缓解率方面优于利妥昔单抗。目前的适应症是：利妥昔单抗难治性低度或滤泡性淋巴瘤，以及复发性或难治性、低度、滤泡性或转化性淋巴瘤。已经启动了额外的研究，以进一步确定这种新疗法在治疗B细胞非霍奇金淋巴瘤患者中的作用。
Conjugated antibodies have been in clinical trials for over 30 years. Immunotoxins, chemotherapy conjugates and radioimmunotherapies have been evaluated. Zevalin, the first conjugated antibody for the treatment of non-hodgkin's lymphoma (NHL) (and the first radioimmunotherapeutic for cancer) was approved by the US FDA on 19 February 2002 (approval is pending in the EEC). Zevalin (90Yttrium ibritumomab tiuxetan) has been in clinical trials since 1992. Several studies have been conducted including a randomized Phase III trial where it showed superiority to rituximab in overall response rate and in complete response rate. The current indications are: low-grade or follicular lymphoma refractory to rituximab, and relapsed or refractory, low-grade, follicular or transformed lymphoma. Additional studies have been initiated to further define the role of this new therapy in the treatment of patients with B-cell non-hodgkin's lymphoma.